We are a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to address significant unmet medical needs in oncology.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
I-Mab Filed 2021 Annual Report on Form 20-F
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer